ProKidney’s stock rockets on ‘intriguing’ news, but analyst doesn’t recommend buying
6 hours ago
3
ProKidney’s stock was the biggest gainer and most actively traded on Tuesday following “very intriguing” news regarding the biotech’s CKD and diabetes treatment.